|
注册号: Registration number: |
ChiCTR2500115047 |
|
最近更新日期: Date of Last Refreshed on: |
2025-12-22 10:18:47 |
|
注册时间: Date of Registration: |
2025-12-22 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
数智驱动的多病共存患者风险分层评估方法及动态适配系统研发与评价 |
|
Public title: |
Development and evaluation of risk stratification assessment method and dynamic adaptation system for patients with multiple diseases driven by data intelligence |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
数智驱动的多病共存患者风险分层评估方法及动态适配系统研发与评价 |
|
Scientific title: |
Development and evaluation of risk stratification assessment method and dynamic adaptation system for patients with multiple diseases driven by data intelligence |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘畅 |
研究负责人: |
陈璐 |
|
Applicant: |
Liu Chang |
Study leader: |
Chen Lu |
|
申请注册联系人电话: Applicant telephone: |
+86 25 6818 2222 |
研究负责人电话:
Study leader's |
+86 25 6818 2222 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chenlu2020@nju.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
gycc2011@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市中山路321号 |
研究负责人通讯地址: |
江苏省南京市中山路321号 |
|
Applicant address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
Study leader's address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京鼓楼医院 |
||
|
Applicant's institution: |
Nanjing Drum Tower Hospital |
||
|
研究负责人所在单位: |
南京鼓楼医院 |
||
|
Affiliation of the Leader: |
Nanjing Drum Tower Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024-505-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京大学医学院附属鼓楼医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Nanjing Drum Tower Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-08-15 00:00:00 | ||
|
伦理委员会联系人: |
戴红阳 |
||
|
Contact Name of the ethic committee: |
Dai Hongyang |
||
|
伦理委员会联系地址: |
江苏省南京市中山路321号 |
||
|
Contact Address of the ethic committee: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 83106666 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
51350367@qq.com |
|
研究实施负责(组长)单位: |
南京鼓楼医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Nanjing Drum Tower Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市中山路321号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 321, Zhongshan Road, Nanjing City, Jiangsu Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南京鼓楼医院临床研究专项资金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Nanjing Drum Tower Hospital Special fund for clinical research |
||||||||||||||||||||||
|
研究疾病: |
多病共存 |
||||||||||||||||||||||
|
Target disease: |
Coexistence of multiple diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
(1)识别多病共存患者疾病进展多维风险因素,构建疾病进展风险分层评估模型,为多病共存患者分层干预方案制定提供理论依据。 (2)探究多病共存患者疾病进展机理,构建多病共存患者分层干预方案,据此研发多病共存患者智能动态适配系统,并进行系统安全度量和灵敏度测量。 (3)探究多病共存患者智能动态适配系统的应用效果和经济学价值,优化基于多元主体的多病共存患者健康管理政策,为政府部门出台相关健康管理政策提供参考依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
(1) To identify multidimensional risk factors for disease progression in patients with multiple diseases, construct a stratified risk assessment model for disease progression, and provide theoretical basis for formulating stratified intervention plans for patients with multiple diseases. (2) To explore the disease progression mechanism of patients with multiple diseases, construct a hierarchical intervention scheme for patients with multiple diseases, develop an intelligent dynamic adaptation system for patients with multiple diseases, and measure system safety and sensitivity. (3) Explore the application effect and economic value of the intelligent dynamic adaptation system for patients with multiple diseases, optimize health management policies for patients with multiple diseases based on multiple agents, and provide reference for government departments to introduce relevant health management policies. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.本研究开始前4周内曾参加过其他试验; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Other trials were conducted within 4 weeks prior to the start of the study; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-01-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-05-23 00:00:00 至 To 2026-05-23 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
使用SPSS产生随机数字序列,每位研究对象对应一个随机数字,将全部随机数字从小到大编码,规定偶数为对照组,奇数为干预组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
SPSS was used to generate a sequence of random numbers, with each study object corresponding to a random number. All random numbers were coded from smallest to largest, and even numbers were specified as the control group and odd numbers as the intervention group. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
开放标签 |
|
Blinding: |
Open-label study |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过ResMan(www.medresman.org.cn)方式共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the end of the study, it was shared by ResMan (www.medresman.org.cn). |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF;EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF;EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |